TNF‐α‐mediated reduction in PGC‐1α may impair skeletal muscle function after cigarette smoke exposure

Skeletal muscle dysfunction contributes to exercise limitation in COPD. In this study cigarette smoke exposure was hypothesized to increase expression of the inflammatory cytokine, TNF‐α, thereby suppressing PGC‐1α, and hence affecting down stream molecules that regulate oxygen transport and muscle function. Furthermore, we hypothesized that highly vascularized oxidative skeletal muscle would be more susceptible to cigarette smoke than less well‐vascularized glycolytic muscle. To test these hypotheses, mice were exposed to cigarette smoke daily for 8 or 16 weeks, resulting in 157% (8 weeks) and 174% (16 weeks) increases in serum TNF‐α. Separately, TNF‐α administered to C2C12 myoblasts was found to dose‐dependently reduce PGC‐1α mRNA. In the smoke‐exposed mice, PGC‐1α mRNA was decreased, by 48% in soleus and 23% in EDL. The vascular PGC‐1α target molecule, VEGF, was also down‐regulated, but only in the soleus, which exhibited capillary regression and an oxidative to glycolytic fiber type transition. The apoptosis PGC‐1α target genes, atrogin‐1 and MuRF1, were up‐regulated, and to a greater extent in the soleus than EDL. Citrate synthase (soleus—19%, EDL—17%) and β‐hydroxyacyl CoA dehydrogenase (β‐HAD) (soleus—22%, EDL—19%) decreased similarly in both muscle types. There was loss of body and gastrocnemius complex mass, with rapid soleus but not EDL fatigue and diminished exercise endurance. These data suggest that in response to smoke exposure, TNF‐α‐mediated down‐regulation of PGC‐1α may be a key step leading to vascular and myocyte dysfunction, effects that are more evident in oxidative than glycolytic skeletal muscles. J. Cell. Physiol. 222: 320–327, 2010. © 2009 Wiley‐Liss, Inc.

[1]  Y. Hellsten,et al.  PGC-1alpha mediates exercise-induced skeletal muscle VEGF expression in mice. , 2009, American journal of physiology. Endocrinology and metabolism.

[2]  H. Pilegaard,et al.  The role of PGC-1alpha on mitochondrial function and apoptotic susceptibility in muscle. , 2009, American journal of physiology. Cell physiology.

[3]  M. Polkey,et al.  Altered Body Composition and Muscle Anabolic, Catabolic and Metabolic Gene Expression in COPD Patients with Elevated Skeletal Muscle Inflammation. , 2009, ATS 2009.

[4]  M. Tisdale Mechanisms of cancer cachexia. , 2009, Physiological reviews.

[5]  G. Joos,et al.  Extrapulmonary manifestations of chronic obstructive pulmonary disease in a mouse model of chronic cigarette smoke exposure. , 2009, American journal of respiratory cell and molecular biology.

[6]  D. Taillandier,et al.  Role of the ubiquitin-proteasome pathway in muscle atrophy in cachexia , 2008, Current opinion in supportive and palliative care.

[7]  W. Mizunoya,et al.  Protocol for high-resolution separation of rodent myosin heavy chain isoforms in a mini-gel electrophoresis system. , 2008, Analytical biochemistry.

[8]  A. Musarò,et al.  Measuring Mechanical Properties, Including Isotonic Fatigue, of Fast and Slow MLC/mIgf-1 Transgenic Skeletal Muscle , 2008, Annals of Biomedical Engineering.

[9]  B. Spiegelman,et al.  HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α , 2008, Nature.

[10]  B. Spiegelman,et al.  Skeletal Muscle Fiber-type Switching, Exercise Intolerance, and Myopathy in PGC-1α Muscle-specific Knock-out Animals* , 2007, Journal of Biological Chemistry.

[11]  M. Polkey,et al.  Cytokine profile in quadriceps muscles of patients with severe COPD , 2007, Thorax.

[12]  P. Schrauwen,et al.  Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD , 2007, European Respiratory Journal.

[13]  Jiandie D. Lin,et al.  PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription , 2006, Proceedings of the National Academy of Sciences.

[14]  K. Myburgh,et al.  Electrophoretic separation of human skeletal muscle myosin heavy chain isoforms: the importance of reducing agents. , 2006, The journal of physiological sciences : JPS.

[15]  M. Morris,et al.  Cigarette smoke exposure reprograms the hypothalamic neuropeptide Y axis to promote weight loss. , 2006, American journal of respiratory and critical care medicine.

[16]  S. Bozinovski,et al.  Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease). , 2006, Pharmacology & therapeutics.

[17]  E. Wouters,et al.  Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. , 2006, American journal of respiratory cell and molecular biology.

[18]  Jiandie D. Lin,et al.  Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. , 2005, Cell metabolism.

[19]  K. Tang,et al.  Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. , 2004, Physiological genomics.

[20]  P. Barnes,et al.  New concepts in chronic obstructive pulmonary disease. , 2003, Annual review of medicine.

[21]  F. Booth,et al.  Molecular regulation of individual skeletal muscle fibre types. , 2003, Acta physiologica Scandinavica.

[22]  Jiandie D. Lin,et al.  Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres , 2002, Nature.

[23]  Jiandie D. Lin,et al.  Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. , 2002, Nature.

[24]  J. Barberà,et al.  Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[25]  H. Saito,et al.  The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor- α System in Patients with Chronic Obstructive Pulmonary Disease , 2000 .

[26]  H. Saito,et al.  The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[27]  E. Wouters,et al.  Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[28]  Chronic obstructive pulmonary disease: capillarity and fiber-type characteristics of skeletal muscle. , 1998, Journal of cardiopulmonary rehabilitation.

[29]  F. Maltais,et al.  Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. , 1998, Medicine and science in sports and exercise.

[30]  F. Maltais,et al.  Metabolic and hemodynamic responses of lower limb during exercise in patients with COPD. , 1998, Journal of applied physiology.

[31]  S. Shapiro,et al.  Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. , 1997, Science.

[32]  E. Wouters,et al.  Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. , 1996, Thorax.

[33]  P. Wagner,et al.  Angiogenic growth factor mRNA responses in muscle to a single bout of exercise. , 1996, Journal of applied physiology.

[34]  J. Mege,et al.  Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. , 1994, American journal of respiratory and critical care medicine.

[35]  A. Benabid,et al.  Metabolism and aerobic capacity of skeletal muscle in chronic respiratory failure related to chronic obstructive pulmonary disease. , 1992, The European respiratory journal.

[36]  A. Churg,et al.  Cigarette smoke causes physiologic and morphologic changes of emphysema in the guinea pig. , 1990, The American review of respiratory disease.

[37]  M. Grim,et al.  Enzymatic heterogeneity of the capillary bed of rat skeletal muscles. , 1986, The American journal of anatomy.

[38]  M. Danson,et al.  Citrate synthase. , 2020, Current topics in cellular regulation.

[39]  P. Srere,et al.  [1] Citrate synthase. [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)] , 1969 .